Filing identity and business context
Important metadata discrepancy: The supplied filing is Caladrius Biosciences, Inc.’s Form 10-Q for the quarter ended June 30, 2017—not a Lisata Therapeutics, Inc. filing for 2016 Q2. The summary below reflects the filing text provided.
Caladrius develops cellular therapies. Its lead program, CLBS03, is a Phase 2 Treg therapy for recent-onset type 1 diabetes in adolescents. On May 18, 2017, the company sold its remaining 80.1% interest in PCT to Hitachi; PCT is presented as discontinued operations. The financial statements give retroactive effect to a one-for-ten reverse stock split.
Financial results and liquidity
| Metric | Three months ended June 30, 2017 | Six months ended June 30, 2017 | Comparable 2016 period |
|---|---|---|---|
| Continuing-operations revenue | No revenue reported | No revenue reported | No revenue reported |
| Operating expenses | $7.71 million | $14.14 million | $7.41 million; $18.28 million |
| Loss from continuing operations | $2.02 million | $8.66 million | $7.73 million; $19.50 million |
| Net income (loss) | $38.47 million | $28.67 million | $(7.88) million; $(19.93) million |
| Operating cash used, continuing operations | Not provided for the quarter | $14.94 million | $17.18 million for six months |
Net income in 2017 was driven by the PCT sale, not continuing operations: the company recorded a $51.74 million gain on sale. Discontinued operations contributed $40.49 million of income for the quarter and $37.33 million for the six months, after related items including tax expense. PCT reported revenue of $5.73 million for the quarter and $16.04 million for the six months before its sale; these are discontinued-operations figures.
For the six months, R&D was $8.00 million, down 24% from $10.54 million; G&A was $6.14 million, down 21% from $7.74 million. Quarterly operating expenses rose 4% year over year, with higher G&A and CLBS03 spending partly offset by lower other program costs. No continuing-operations revenue or gross margin is reported.
At June 30, cash and cash equivalents were $23.04 million, restricted cash $5.00 million, and marketable securities $36.32 million. Together these totaled approximately $64.37 million, including restricted cash. Working capital was approximately $55.9 million. Long-term debt was fully repaid in May; notes payable totaled about $0.60 million, current and noncurrent combined. Six-month cash flow included $26.83 million provided by investing activities, substantially reflecting PCT sale proceeds, and $2.91 million used in financing activities. Stockholders’ equity was $54.42 million.
Material changes, outlook and risks
- PCT divestiture: The stated consideration was $75.0 million plus an approximately $4.4 million cash adjustment and a potential $5.0 million milestone if PCT reaches $125 million of qualifying cumulative revenue during 2017–2018. The milestone’s fair value was recorded as zero at closing. $5.0 million was placed in escrow for potential indemnification claims, with release scheduled for June 2018 subject to claims. The $4.4 million adjustment was received in July 2017.
- Debt and financing: The Oxford Finance loan was retired in May for $4.9 million, including principal, interest and early-termination fees. The company also raised equity through Sanford Health and its Aspire agreement. It said cash on hand was expected to fund CLBS03 development and other expenses for at least 12 months from the financial-statement issuance date, while warning that further capital may be needed and may not be available on acceptable terms.
- Clinical outlook: A CLBS03 interim analysis of early therapeutic effect was expected in late 2017 or early 2018, after about half of patients reached six-month follow-up. CIRM awarded up to $12.2 million for the T-Rex Study; $5.7 million had been received by June 30, subject to milestones and eligible costs. CLBS03 had FDA Fast Track and orphan-drug designations. The company was seeking partners or grant funding for other programs, including CLBS12 for critical limb ischemia.
- Unusual expenses and tax: The sale triggered accelerated vesting of equity awards and approximately $1.9 million of equity-compensation expense; additional sale-related transaction and retention costs were approximately $6.9 million. A $5.89 million income-tax benefit was recorded for continuing operations. Management said it expected continuing-operations losses for the remainder of 2017 and anticipated retaining a valuation allowance on remaining deferred tax assets.
- Risks and contingencies: Risks include clinical and regulatory uncertainty, patient enrollment and trial execution, dependence on external financing or partnerships, possible dilution, sale-related indemnification claims, and whether PCT achieves the milestone. The filing reported no material changes to previously disclosed risk factors and no material pending legal claims expected to adversely affect financial condition or results.
Key facts for investors to verify
- Confirm the intended company and reporting period: the supplied document identifies Caladrius Biosciences and Q2 2017, contrary to the request metadata.
- Distinguish recurring operating performance from the one-time PCT sale gain when assessing reported net income and earnings per share.
- Check the timing and restrictions on the $5.0 million escrow, the July 2017 $4.4 million adjustment, and the conditions for the potential $5.0 million milestone.
- Assess the company’s stated 12-month cash runway against continuing cash burn, trial costs, and access to remaining equity or grant funding.
- Track CLBS03 enrollment and the expected interim analysis, as well as the milestones and eligible-cost conditions attached to CIRM funding.